Loreto Carmona to Arthritis, Rheumatoid
This is a "connection" page, showing publications Loreto Carmona has written about Arthritis, Rheumatoid.
Connection Strength
1.391
-
Practical Aspects of Biological Throught Levels and Antidrug Antibodies in Rheumatoid Arthritis and Spondyloarthritis. Reumatol Clin (Engl Ed). 2020 Sep - Oct; 16(5 Pt 2):378-385.
Score: 0.284
-
Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021 09; 80(9):1137-1146.
Score: 0.085
-
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis. 2020 12; 79(12):1544-1549.
Score: 0.080
-
Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis. J Rheumatol. 2019 09; 46(9):1164-1167.
Score: 0.073
-
Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence. Rheumatol Int. 2018 12; 38(12):2289-2296.
Score: 0.070
-
Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study. Reumatol Clin (Engl Ed). 2020 Mar - Apr; 16(2 Pt 1):116-119.
Score: 0.069
-
The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern. Rheumatol Int. 2018 09; 38(9):1735-1740.
Score: 0.069
-
Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. Rheumatol Int. 2018 Jun; 38(6):975-983.
Score: 0.068
-
The revised Bristol Rheumatoid Arthritis Fatigue measures and the Rheumatoid Arthritis Impact of Disease scale: validation in six countries. Rheumatology (Oxford). 2018 02 01; 57(2):300-308.
Score: 0.067
-
2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. Ann Rheum Dis. 2018 04; 77(4):476-479.
Score: 0.067
-
Are rheumatologists adhering to the concepts window of opportunity and treat-to-target? Earlier and more intense disease-modifying anti-rheumatic drug treatment over time in patients with early arthritis in the PEARL study. Clin Exp Rheumatol. 2018 May-Jun; 36(3):382-388.
Score: 0.067
-
Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. J Rheumatol. 2017 Dec; 44(12):1894-1898.
Score: 0.064
-
Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study. Rheumatol Int. 2017 Jul; 37(7):1195-1202.
Score: 0.064
-
Exploring the remission concept in rheumatoid arthritis with patients and rheumatologists: time for a new approach? Clin Exp Rheumatol. 2017 Sep-Oct; 35(5):816-822.
Score: 0.064
-
Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. Clin Exp Rheumatol. 2017 May-Jun; 35(3):423-430.
Score: 0.062
-
Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis. PLoS One. 2016; 11(12):e0166691.
Score: 0.062
-
Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol. 2015 Jan; 67(1):117-27.
Score: 0.054
-
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020 07; 79(7):859-866.
Score: 0.020